(GKOS) Glaukos - Overview
Sector: HealthcareIndustry: Medical Devices | Exchange NYSE (USA) | Currency USD | Market Cap: 5.865m | Total Return -0.4% in 12m
Stock: Stents, Implants, Pharmaceuticals, Devices
Total Rating 21
Risk 30
Buy Signal -1.27
| Risk 5d forecast | |
|---|---|
| Volatility | 48.0% |
| Relative Tail Risk | -12.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.16 |
| Alpha | -12.63 |
| Character TTM | |
|---|---|
| Beta | 0.986 |
| Beta Downside | 1.637 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.68% |
| CAGR/Max DD | 0.51 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: GKOS Glaukos February 28, 2026
Glaukos Corp (NYSE:GKOS) is a U.S.-based ophthalmic pharma and med-tech firm focused on minimally invasive treatments for glaucoma, corneal disorders, and retinal diseases. Its flagship products include the iStent and iStent inject micro-bypass stents for mild-to-moderate open-angle glaucoma, the iStent infinite for refractory cases, and the iDose TR intracameral therapy. The pipeline expands into keratoconus (iLink), transdermal drug delivery (ILution), and a retinal XR platform targeting AMD, DME, and retinal vein occlusion.
In FY 2023 Glaukos generated $442 million in revenue, a 13% year-over-year increase, with iStent-related sales climbing 22% driven by growing adoption of micro-invasive glaucoma surgery (MIGS). The company now holds roughly 30% of the U.S. MIGS market, while the broader glaucoma market is projected to reach $7.5 billion by 2027 as the aging population expands. Recent FDA clearance of iStent infinite and positive Phase III data for the retinal XR platform have bolstered its growth outlook.
For a deeper dive, consider reviewing ValueRay’s analyst notes on GKOS.
Headlines to watch out for
- iStent glaucoma device sales drive revenue growth
- Regulatory approvals for new ophthalmic therapies impact market access
- Reimbursement policies for glaucoma procedures affect profitability
- Competition from alternative glaucoma treatments pressures market share
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -187.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 4.42 > 1.0 |
| NWC/Revenue: 73.65% < 20% (prev 97.70%; Δ -24.06% < -1%) |
| CFO/TA -0.02 > 3% & CFO -14.8m > Net Income -187.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.5m) vs 12m ago 3.46% < -2% |
| Gross Margin: 79.66% > 18% (prev 0.75%; Δ 7.89k% > 0.5%) |
| Asset Turnover: 54.32% > 50% (prev 39.34%; Δ 14.98% > 0%) |
| Interest Coverage Ratio: -19.84 > 6 (EBITDA TTM -146.2m / Interest Expense TTM 9.26m) |
Altman Z'' -6.10
| A: 0.42 (Total Current Assets 475.0m - Total Current Liabilities 101.3m) / Total Assets 893.5m |
| B: -1.04 (Retained Earnings -933.1m / Total Assets 893.5m) |
| C: -0.20 (EBIT TTM -183.8m / Avg Total Assets 934.1m) |
| D: -3.92 (Book Value of Equity -929.8m / Total Liabilities 237.3m) |
| Altman-Z'' Score: -6.10 = D |
Beneish M -2.92
| DSRI: 1.35 (Receivables 108.6m/60.7m, Revenue 507.4m/383.5m) |
| GMI: 0.95 (GM 79.66% / 75.48%) |
| AQI: 0.72 (AQ_t 0.26 / AQ_t-1 0.36) |
| SGI: 1.32 (Revenue 507.4m / 383.5m) |
| TATA: -0.19 (NI -187.7m - CFO -14.8m) / TA 893.5m) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of GKOS shares?
As of March 29, 2026, the stock is trading at USD 103.18 with a total of 624,540 shares traded.
Over the past week, the price has changed by +2.17%, over one month by -14.30%, over three months by -10.71% and over the past year by -0.42%.
Over the past week, the price has changed by +2.17%, over one month by -14.30%, over three months by -10.71% and over the past year by -0.42%.
Is GKOS a buy, sell or hold?
Glaukos has received a consensus analysts rating of 4.27.
Therefore, it is recommended to buy GKOS.
- StrongBuy: 9
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the GKOS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 134.8 | 30.6% |
| Analysts Target Price | 134.8 | 30.6% |
GKOS Fundamental Data Overview March 29, 2026
P/E Forward = 2000.0
P/S = 11.5587
P/B = 8.939
P/EG = 1.64
Revenue TTM = 507.4m USD
EBIT TTM = -183.8m USD
EBITDA TTM = -146.2m USD
Long Term Debt = 103.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 139.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 48.8m USD (from netDebt column, last quarter)
Enterprise Value = 5.73b USD (5.87b + Debt 139.6m - CCE 278.8m)
Interest Coverage Ratio = -19.84 (Ebit TTM -183.8m / Interest Expense TTM 9.26m)
EV/FCF = -255.0x (Enterprise Value 5.73b / FCF TTM -22.5m)
FCF Yield = -0.39% (FCF TTM -22.5m / Enterprise Value 5.73b)
FCF Margin = -4.43% (FCF TTM -22.5m / Revenue TTM 507.4m)
Net Margin = -36.99% (Net Income TTM -187.7m / Revenue TTM 507.4m)
Gross Margin = 79.66% ((Revenue TTM 507.4m - Cost of Revenue TTM 103.2m) / Revenue TTM)
Gross Margin QoQ = 83.81% (prev 78.41%)
Tobins Q-Ratio = 6.41 (Enterprise Value 5.73b / Total Assets 893.5m)
Interest Expense / Debt = 0.82% (Interest Expense 1.15m / Debt 139.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -145.2m (EBIT -183.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.69 (Total Current Assets 475.0m / Total Current Liabilities 101.3m)
Debt / Equity = 0.21 (Debt 139.6m / totalStockholderEquity, last quarter 656.2m)
Debt / EBITDA = -0.33 (negative EBITDA) (Net Debt 48.8m / EBITDA -146.2m)
Debt / FCF = -2.17 (negative FCF - burning cash) (Net Debt 48.8m / FCF TTM -22.5m)
Total Stockholder Equity = 738.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.09% (Net Income -187.7m / Total Assets 893.5m)
RoE = -25.41% (Net Income TTM -187.7m / Total Stockholder Equity 738.7m)
RoCE = -21.81% (EBIT -183.8m / Capital Employed (Equity 738.7m + L.T.Debt 103.9m))
RoIC = -19.65% (negative operating profit) (NOPAT -145.2m / Invested Capital 738.7m)
WACC = 9.25% (E(5.87b)/V(6.01b) * Re(9.45%) + D(139.6m)/V(6.01b) * Rd(0.82%) * (1-Tc(0.21)))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.47%
[DCF] Fair Price = unknown (Cash Flow -22.5m)
EPS Correlation: 31.01 | EPS CAGR: -47.49% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.02 | Revenue CAGR: 22.10% | SUE: 2.16 | # QB: 7
EPS next Quarter (2026-06-30): EPS=-0.20 | Chg7d=+0.009 | Chg30d=-0.069 | Revisions Net=-8 | Analysts=15
EPS current Year (2026-12-31): EPS=-0.56 | Chg7d=+0.006 | Chg30d=-0.245 | Revisions Net=-5 | Growth EPS=+37.3% | Growth Revenue=+21.0%
EPS next Year (2027-12-31): EPS=0.41 | Chg7d=+0.010 | Chg30d=-0.221 | Revisions Net=-8 | Growth EPS=+171.8% | Growth Revenue=+27.4%
[Analyst] Revisions Ratio: -0.67 (2 Up / 10 Down within 30d for Next Quarter)
P/S = 11.5587
P/B = 8.939
P/EG = 1.64
Revenue TTM = 507.4m USD
EBIT TTM = -183.8m USD
EBITDA TTM = -146.2m USD
Long Term Debt = 103.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 139.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 48.8m USD (from netDebt column, last quarter)
Enterprise Value = 5.73b USD (5.87b + Debt 139.6m - CCE 278.8m)
Interest Coverage Ratio = -19.84 (Ebit TTM -183.8m / Interest Expense TTM 9.26m)
EV/FCF = -255.0x (Enterprise Value 5.73b / FCF TTM -22.5m)
FCF Yield = -0.39% (FCF TTM -22.5m / Enterprise Value 5.73b)
FCF Margin = -4.43% (FCF TTM -22.5m / Revenue TTM 507.4m)
Net Margin = -36.99% (Net Income TTM -187.7m / Revenue TTM 507.4m)
Gross Margin = 79.66% ((Revenue TTM 507.4m - Cost of Revenue TTM 103.2m) / Revenue TTM)
Gross Margin QoQ = 83.81% (prev 78.41%)
Tobins Q-Ratio = 6.41 (Enterprise Value 5.73b / Total Assets 893.5m)
Interest Expense / Debt = 0.82% (Interest Expense 1.15m / Debt 139.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -145.2m (EBIT -183.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.69 (Total Current Assets 475.0m / Total Current Liabilities 101.3m)
Debt / Equity = 0.21 (Debt 139.6m / totalStockholderEquity, last quarter 656.2m)
Debt / EBITDA = -0.33 (negative EBITDA) (Net Debt 48.8m / EBITDA -146.2m)
Debt / FCF = -2.17 (negative FCF - burning cash) (Net Debt 48.8m / FCF TTM -22.5m)
Total Stockholder Equity = 738.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.09% (Net Income -187.7m / Total Assets 893.5m)
RoE = -25.41% (Net Income TTM -187.7m / Total Stockholder Equity 738.7m)
RoCE = -21.81% (EBIT -183.8m / Capital Employed (Equity 738.7m + L.T.Debt 103.9m))
RoIC = -19.65% (negative operating profit) (NOPAT -145.2m / Invested Capital 738.7m)
WACC = 9.25% (E(5.87b)/V(6.01b) * Re(9.45%) + D(139.6m)/V(6.01b) * Rd(0.82%) * (1-Tc(0.21)))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.47%
[DCF] Fair Price = unknown (Cash Flow -22.5m)
EPS Correlation: 31.01 | EPS CAGR: -47.49% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.02 | Revenue CAGR: 22.10% | SUE: 2.16 | # QB: 7
EPS next Quarter (2026-06-30): EPS=-0.20 | Chg7d=+0.009 | Chg30d=-0.069 | Revisions Net=-8 | Analysts=15
EPS current Year (2026-12-31): EPS=-0.56 | Chg7d=+0.006 | Chg30d=-0.245 | Revisions Net=-5 | Growth EPS=+37.3% | Growth Revenue=+21.0%
EPS next Year (2027-12-31): EPS=0.41 | Chg7d=+0.010 | Chg30d=-0.221 | Revisions Net=-8 | Growth EPS=+171.8% | Growth Revenue=+27.4%
[Analyst] Revisions Ratio: -0.67 (2 Up / 10 Down within 30d for Next Quarter)